Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senl_1904A vs Senl_1904B CAR-T in r/r B-ALL
NCT03840317Phase 1Unknown
- Sponsor
- Senlang Bio
- Start
- Jan 2019
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in acute lymphoblastic leukemia (ALL) comparing Senl_1904A with Senl_1904B (2 arms). Primary endpoint: Tumor load at 1 month. Status: unknown.
02
Drugs
sl1904bSENL_1904A
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03840317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840317.